Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial is a research paper published in Nature Medicine (2022). On theSindex it has a DataRank of 0. It has been cited 57 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NIDDK NIH HHS
Grant: P30 DK020579
NIDDK NIH HHS
Grant: R44 DK108305
NIDDK NIH HHS
Grant: P30 DK056341
MeSH Terms